Amwell Beats Earnings, Misses Revenue, and Raises Guidance

American Well reported fiscal 2026 Q2 earnings on Aug 04th, 2026.

American Well delivered mixed results for Q2 2026, surpassing analyst expectations on profitability but falling short on revenue. The company reported an adjusted loss of $0.59 per share, beating the consensus estimate of $0.86, while total revenue of $52.05 million missed the $49.87 million projection. Furthermore, management raised its full-year 2026 financial outlook, signaling improved confidence in its path to profitability despite near-term revenue challenges.

Revenue

The total revenue of American Well decreased by 26.6% to $52.05 million in 2026 Q2, down from $70.90 million in 2025 Q2.

Earnings/Net Income

American Well narrowed losses to $0.59 per share in 2026 Q2 from a loss of $1.24 per share in 2025 Q2 (52.4% improvement). Meanwhile, the company successfully narrowed its net loss to $-9.63 million in 2026 Q2, reducing losses by 50.7% compared to the $-19.53 million net loss reported in 2025 Q2. The Company has sustained losses for 8 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS performance was positive as the loss per share improved significantly year-over-year and beat consensus estimates.

Price Action

The stock price of American Well has edged down 2.53% during the latest trading day, has dropped 6.04% during the most recent full trading week, and has jumped 12.65% month-to-date.

Post-Earnings Price Action Review

The "buy on a revenue beat, hold for 30 days" strategy yielded weak results for AMWL following its Q2 2026 earnings release. Although the company beat revenue estimates, the stock closed at $10.42 on August 4, 2026, and only rose to $10.76 by August 31, 2026, representing a modest +3.26% return. This limited gain occurred despite the earnings beat, as the stock had already experienced a short-term downtrend leading into the report, dropping from $12.58 on July 20 to $10.42 on the earnings date. Consequently, the post-earnings movement appears to be a mean reversion bounce rather than a strong trend continuation. This single data point suggests that AMWL may not be an ideal candidate for simple revenue-beat momentum holds, as the follow-through was lackluster. However, this conclusion is based on only one earnings event and lacks statistical robustness; a comprehensive backtest across multiple quarters would be necessary to validate this observation and separate signal from noise.

CEO Commentary

Dr. Ido Schoenberg, Chairman and CEO, Amwell, emphasized the strategic milestone of the Defense Health Agency’s intent to award a sole-source contract, signaling long-term trust in Amwell as core infrastructure for the Military Health System. He highlighted a pivotal shift from a telehealth vendor to an infrastructure provider for AI-powered care, addressing payer vendor sprawl through a unified platform that simplifies member engagement and outcome measurement. The company is achieving financial discipline, nearing adjusted EBITDA breakeven, driven by a subscription revenue mix exceeding half of total revenue. Schoenberg expressed strong optimism, citing independently validated clinical results, a growing pipeline, and a laser-focused strategy that prioritizes a single, reliable platform over fragmented solutions, positioning Amwell for durable growth as AI accelerates in healthcare.

Guidance

Amwell raised its full-year 2026 financial outlook, projecting total revenue between $200 million and $205 million, up from a previous low-end estimate of $195 million. Adjusted EBITDA guidance was significantly improved to a loss range of negative $9 million to negative $7 million, compared to the prior expectation of a loss between $12 million and $16 million. For the third quarter of 2026, the company expects revenue of $46 million to $48 million with an Adjusted EBITDA loss of negative $5 million to negative $3 million, reflecting normal seasonal visit volume fluctuations and costs from completing internal projects. Management reaffirmed its commitment to achieving positive adjusted EBITDA and positive operating cash flow by the fourth quarter of 2026, supported by a disciplined cost structure and strong subscription stability.

Additional News

Insider activity remains a focal point for American Well investors, with company insiders selling 29,225 shares worth $268,623 over the past 90 days. Despite these sales, institutional investors and hedge funds continue to hold a significant stake, owning 56.05% of the company. Analyst sentiment is mixed but showing signs of divergence; while Weiss Ratings reiterated a "sell (d-)" rating on July 17, Wells Fargo upgraded its outlook, raising its price target from $9.00 to $16.00 and assigning an "overweight" rating on the same date. Morgan Stanley also adjusted its view in May, increasing its target from $6.00 to $6.50 with an "equal weight" rating. Currently, the consensus rating among analysts remains a "Hold," with an average price target of $8.60. The stock has traded between a 52-week low of $3.71 and a high of $13.45, with recent volume averaging 96,093 shares compared to the recent trading day's 144,344 shares.